Positive Five-Year Outcomes Seen for Nivolumab in Resectable Lung Cancer

WEDNESDAY, Feb. 15, 2023 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant nivolumab is associated with positive five-year outcomes, according to a study published online Feb. 15 in Clinical Cancer Research. Samuel...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news